JP2018523686A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018523686A5 JP2018523686A5 JP2018508741A JP2018508741A JP2018523686A5 JP 2018523686 A5 JP2018523686 A5 JP 2018523686A5 JP 2018508741 A JP2018508741 A JP 2018508741A JP 2018508741 A JP2018508741 A JP 2018508741A JP 2018523686 A5 JP2018523686 A5 JP 2018523686A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tumor
- diabody
- cell carcinoma
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562206051P | 2015-08-17 | 2015-08-17 | |
| US62/206,051 | 2015-08-17 | ||
| US201662280318P | 2016-01-19 | 2016-01-19 | |
| US62/280,318 | 2016-01-19 | ||
| PCT/US2016/046680 WO2017030926A1 (en) | 2015-08-17 | 2016-08-12 | Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018523686A JP2018523686A (ja) | 2018-08-23 |
| JP2018523686A5 true JP2018523686A5 (enExample) | 2019-08-08 |
Family
ID=58051498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018508741A Pending JP2018523686A (ja) | 2015-08-17 | 2016-08-12 | Ｂ７‐ｈ３及びｃｄ３に結合できる二重特異性１価ダイアボディ並びにその使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20190002563A1 (enExample) |
| EP (1) | EP3337507A4 (enExample) |
| JP (1) | JP2018523686A (enExample) |
| KR (1) | KR20180038045A (enExample) |
| CN (1) | CN107921130A (enExample) |
| AU (1) | AU2016307955A1 (enExample) |
| CA (1) | CA2995709A1 (enExample) |
| CL (1) | CL2018000422A1 (enExample) |
| CO (1) | CO2018001485A2 (enExample) |
| CR (1) | CR20180105A (enExample) |
| EA (1) | EA201890443A1 (enExample) |
| EC (1) | ECSP18011248A (enExample) |
| HK (1) | HK1249423A1 (enExample) |
| IL (1) | IL257562A (enExample) |
| MA (1) | MA42665A (enExample) |
| MX (1) | MX2018001954A (enExample) |
| PE (1) | PE20181066A1 (enExample) |
| PH (1) | PH12018500363A1 (enExample) |
| TW (1) | TW201718652A (enExample) |
| WO (1) | WO2017030926A1 (enExample) |
| ZA (1) | ZA201800955B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201913680PA (en) * | 2014-05-29 | 2020-03-30 | Macrogenics Inc | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
| AP2017009823A0 (en) | 2014-09-26 | 2017-03-31 | Macrogenics Inc | Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof |
| JP6955507B2 (ja) | 2015-12-14 | 2021-10-27 | マクロジェニクス，インコーポレーテッド | Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法 |
| JP7132232B2 (ja) | 2017-02-24 | 2022-09-06 | マクロジェニクス，インコーポレーテッド | Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用 |
| WO2018191438A1 (en) | 2017-04-11 | 2018-10-18 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
| WO2019051102A2 (en) * | 2017-09-08 | 2019-03-14 | Maverick Therapeutics, Inc. | Constrained conditionally activated binding proteins |
| CN109939230A (zh) * | 2017-12-21 | 2019-06-28 | 张曼 | 关于cd3×b7h3双特异性抗体定向杀伤耐顺铂膀胱癌细胞t24/ddp的应用 |
| CN109939231A (zh) * | 2017-12-21 | 2019-06-28 | 张曼 | 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞t24的应用 |
| CN109939126A (zh) * | 2017-12-21 | 2019-06-28 | 张曼 | Cd3×b7h3双特异抗体定向杀伤耐阿霉素膀胱癌细胞pumc-91/adm的应用 |
| CN109939232A (zh) * | 2017-12-21 | 2019-06-28 | 张曼 | 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞pumc-91的应用 |
| CN109971711A (zh) * | 2017-12-27 | 2019-07-05 | 张曼 | 关于cd3×b7h3双特异性抗体定向杀伤人膀胱癌细胞的应用 |
| SG11202007572VA (en) * | 2018-02-15 | 2020-09-29 | Macrogenics Inc | Variant cd3-binding domains and their use in combination therapies for the treatment of disease |
| IL277863B2 (en) | 2018-04-11 | 2026-02-01 | Inhibrx Inc | Multispecific polypeptide constructs with forced CD3 binding and related methods and uses |
| TWI848953B (zh) * | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| CA3105891A1 (en) | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| CN109762068A (zh) * | 2018-08-09 | 2019-05-17 | 源道隆（苏州）医学科技有限公司 | 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用 |
| WO2020077257A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
| CA3115082A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | B7h3 single domain antibodies and therapeutic compositions thereof |
| CN112969476B (zh) * | 2018-12-07 | 2024-06-14 | 江苏恒瑞医药股份有限公司 | 多特异性蛋白分子 |
| CN112955471B (zh) | 2018-12-07 | 2022-11-22 | 江苏恒瑞医药股份有限公司 | Cd3抗体及其药物用途 |
| KR102732027B1 (ko) * | 2019-07-09 | 2024-11-20 | 주식회사 와이바이오로직스 | B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도 |
| CN111454357B (zh) * | 2019-08-14 | 2022-03-15 | 康诺亚生物医药科技（成都）有限公司 | 一种含有抗体的肿瘤治疗剂的开发和应用 |
| EP3822288A1 (en) * | 2019-11-18 | 2021-05-19 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof |
| MX2022007790A (es) * | 2019-12-23 | 2022-10-18 | Macrogenics Inc | Terapia para el tratamiento del cancer. |
| IL294879A (en) | 2020-01-29 | 2022-09-01 | Inhibrx Inc | Monodomain antibodies of cd28 and their multivalent and multispecific constructs |
| CA3189590A1 (en) * | 2020-07-17 | 2022-01-20 | Pfizer Inc. | Therapeutic antibodies and their uses |
| EP4032910A1 (en) * | 2021-01-22 | 2022-07-27 | ETH Zurich | Bispecific binding agent that binds to cd3 and a fluorophore |
| US20240218069A1 (en) * | 2021-04-28 | 2024-07-04 | Lyvgen Biopharma Holdings Limited | Bi-specific antibodies comprising anti-b7h3 binding molecules |
| CN113527493B (zh) * | 2021-07-20 | 2023-10-27 | 广州爱思迈生物医药科技有限公司 | 一种b7-h3抗体及其应用 |
| US20230151095A1 (en) | 2021-11-12 | 2023-05-18 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
| CN114539420B (zh) * | 2022-01-20 | 2024-05-17 | 荣昌生物制药(烟台)股份有限公司 | 抗b7-h3单克隆抗体、抗b7-h3×cd3双特异性抗体、制备方法及其应用 |
| CN117903311B (zh) * | 2024-03-20 | 2024-10-25 | 湖南卓润生物科技有限公司 | sST2特异性结合蛋白及其制备方法和应用 |
| WO2025245264A1 (en) * | 2024-05-21 | 2025-11-27 | Briapro Therapeutics Corp. | Anti-b7-h3 antibodies and methods of use thereof |
| WO2026008059A1 (en) * | 2024-07-04 | 2026-01-08 | Nanjing Legend Biotech Co., Ltd. | Anti-dll3 constructs and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12018501083A1 (en) * | 2010-03-04 | 2019-02-18 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| US9587021B2 (en) * | 2011-05-21 | 2017-03-07 | Macrogenics, Inc. | CD3-binding molecules capable of binding to human and non-human CD3 |
| US10851178B2 (en) * | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US9487587B2 (en) * | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| US20140302037A1 (en) * | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| UA116479C2 (uk) * | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ |
| EP2839842A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| CN108136010A (zh) * | 2015-10-08 | 2018-06-08 | 宏观基因有限公司 | 用于治疗癌症的联合疗法 |
-
2016
- 2016-08-12 WO PCT/US2016/046680 patent/WO2017030926A1/en not_active Ceased
- 2016-08-12 CN CN201680048182.7A patent/CN107921130A/zh active Pending
- 2016-08-12 EP EP16837560.8A patent/EP3337507A4/en not_active Withdrawn
- 2016-08-12 US US15/752,367 patent/US20190002563A1/en not_active Abandoned
- 2016-08-12 PE PE2018000249A patent/PE20181066A1/es unknown
- 2016-08-12 HK HK18109035.8A patent/HK1249423A1/zh unknown
- 2016-08-12 KR KR1020187007443A patent/KR20180038045A/ko not_active Withdrawn
- 2016-08-12 CR CR20180105A patent/CR20180105A/es unknown
- 2016-08-12 JP JP2018508741A patent/JP2018523686A/ja active Pending
- 2016-08-12 MX MX2018001954A patent/MX2018001954A/es unknown
- 2016-08-12 MA MA042665A patent/MA42665A/fr unknown
- 2016-08-12 CA CA2995709A patent/CA2995709A1/en not_active Abandoned
- 2016-08-12 AU AU2016307955A patent/AU2016307955A1/en not_active Abandoned
- 2016-08-12 EA EA201890443A patent/EA201890443A1/ru unknown
- 2016-08-16 TW TW105126154A patent/TW201718652A/zh unknown
-
2018
- 2018-02-13 ZA ZA2018/00955A patent/ZA201800955B/en unknown
- 2018-02-15 CL CL2018000422A patent/CL2018000422A1/es unknown
- 2018-02-15 IL IL257562A patent/IL257562A/en unknown
- 2018-02-15 PH PH12018500363A patent/PH12018500363A1/en unknown
- 2018-02-15 CO CONC2018/0001485A patent/CO2018001485A2/es unknown
- 2018-02-15 EC ECIEPI201811248A patent/ECSP18011248A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12497465B2 (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| CN108473565B (zh) | Ctla4结合剂 | |
| CN109071639B (zh) | Pd1/ctla4结合剂 | |
| US20230110128A1 (en) | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor | |
| JP2020508317A5 (enExample) | ||
| CN111133005B (zh) | 程序性细胞死亡蛋白1抗体 | |
| MX2024007356A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso. | |
| JP2020536109A5 (enExample) | ||
| JP2016509582A5 (enExample) | ||
| IL321717A (en) | Anti-PD-1 antibodies for the treatment of lung cancer | |
| JP2009539380A5 (enExample) | ||
| JP7459058B2 (ja) | Ｃｄ１３７／ｈｅｒ２二重特異性物質とｐｄ－１系阻害物質とを含む併用療法およびその使用法 | |
| JP2020529469A5 (enExample) | ||
| CN116251196A (zh) | 抗-edb抗体和抗体-药物缀合物 | |
| Pan et al. | Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement | |
| EP4366782A1 (en) | Conjugates of checkpoint inhibitors with il-2, and uses thereof | |
| JP2022541591A5 (enExample) | ||
| CN109663130B (zh) | Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| EP4041769A1 (en) | Antibody-drug conjugates specific for cd276 and uses thereof | |
| CN111655725A (zh) | 用于治疗癌症的组合产品 | |
| JP2021531263A (ja) | 抗ヒトｐｄ−ｌ１抗体とその使用 | |
| Lacek et al. | Development of an innovative bifunctional CPL976-MMAE conjugate based on a bispecific anti-PD-L1/ant-AXL antibody with a dual mechanism of action | |
| TWI814752B (zh) | 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途 | |
| JP2019531254A5 (enExample) | ||
| US20260139074A1 (en) | Combination of antibody-drug conjugate and tubulin inhibitor |